Search Bar & Filters
Found 32 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the Edwards SAPIEN X4X4S Transcatheter Heart Valve THV in people at high or greater surgical risk who have a failing aortic bioprosthetic valve. The study is a prospective, single-arm, multicenter trial focusing on participants with specific heart valve issues such as aortic valve insufficiency or stenosis. Participants will receive a transcatheter aortic valve replacement TAVR implant using the SAPIEN X4X4S valve. The study includes two groups those with a failing aortic surgical valve and those with a failing aortic transcatheter heart valve. The procedure involves implanting the device to address valve failure, with no placebo or comparison group, and the study is non-randomized. During the trial, participants will be monitored through various assessments including death and stroke rates at one year, Kansas City Cardiomyopathy Questionnaire KCCQ scores, and New York Heart Association NYHA functional class evaluations at 30 days and one year. These evaluations will help measure health status and heart function. The study will continue until 2039, with primary outcomes assessed at one year after treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Edwards SAPIEN X4 and X4S Transcatheter Heart Valves in people with severe, symptomatic calcific aortic stenosis. This is a prospective, single-arm, multicenter study that includes a separate registry for subjects with bicuspid aortic valve morphology. The study aims to provide important data on these balloon-expandable bioprosthetic valves in this patient population. Participants will undergo a transcatheter aortic valve replacement TAVR procedure using either the SAPIEN X4 or SAPIEN X4S valve. Those with bicuspid aortic valves will be enrolled in a separate registry and also undergo TAVR. The study involves implantation of the valve device via catheter, with no randomization or comparison groups. The primary study period extends up to one year after the procedure. During the study, participants will be monitored through regular assessments including evaluation of survival and stroke occurrence at one year. Secondary outcomes include quality of life measured by the Kansas City Cardiomyopathy Questionnaire, paravalvular leak assessment at 30 days, and new permanent pacemaker implantation also at 30 days. Edwards Lifesciences sponsors the study, and participants will be followed until study completion in 2037 to monitor safety and effectiveness outcomes.
Actively Recruiting
Researchers are evaluating a new atrioventricular interval modulation AVIM algorithm programmed into a dual-chamber Medtronic AstraAzure pacemaker. This trial is designed to assess the safety and effectiveness of this device-based therapy in patients who have hypertension and either already have or need a dual-chamber pacemaker. The study is randomized, double-blind, and conducted across multiple countries. The study has three phases an initial screening phase, followed by a one-year double-blind randomized phase where participants are assigned to either have the AVIM therapy turned on or off, while continuing their stable antihypertensive medication. After this, there is a two-year unblinded phase for further observation. The investigational AVIM therapy is delivered through the pacemaker device. Participants will be monitored for changes in their 24-hour ambulatory systolic blood pressure and for any unexpected serious adverse effects related to the device. Assessments will be done at baseline and three months after randomization, with ongoing evaluation during the two-year follow-up. The entire study duration can last up to three years, including screening and all treatment phases.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are assessing three different methods to prevent peripheral neuropathy caused by taxane chemotherapy drugs like paclitaxel or docetaxel. This phase III trial compares cryocompression, continuous compression, and low cyclic compression therapies using the Paxman Limb Cryocompression System, which applies cooling andor pressure to the arms and legs. The study aims to see if any of these approaches can reduce the nerve damage that leads to numbness, tingling, or pain during chemotherapy. Participants are randomly assigned to one of three groups cryocompression therapy cooling plus moderate and low pressure, continuous compression therapy steady moderate pressure, or low cyclic compression therapy low pressure that cycles on and off. Each therapy is applied for 30 minutes before, during, and after each taxane chemotherapy infusion. Blood, serum, and plasma samples may be collected during screening and throughout the study. During the study, participants will complete questionnaires and undergo evaluations of nerve function and physical tests at multiple time points up to 52 weeks. Researchers will monitor side effects related to the devices, participant satisfaction, and chemotherapy dosing impacts. The main outcome measured is the occurrence of clinically meaningful chemotherapy-induced peripheral neuropathy at 12 weeks after starting treatment, with additional assessments over time to understand the therapies effects and tolerability.
1-10 of 32
1